On July 10, 2020, Beroni Group Limited (“Beroni”), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, announced that it was collaborating with Forsitech Inc. and Standard Capital Co., Ltd (“Standard Capital”) to supply its SARS-CoV-2 total antibody detection kit for clinical testing in the Japanese market. Beroni will start with a supply of 100,000 test kits to be distributed by these two Japanese partners.
The ALLEX platform, a digital STO (security token offerings) exchange solution developed by Standard Capital will be used to ensure smooth and fast delivery of the test kits to the Japanese market. It will also provide necessary and timely information updates, and the system will incorporate a service that recommends retesting 14 days after the initial testing. Given the current global pandemic situation, asymptomatic patients pose a significant risk of infection and should be tested early for presence of antibodies to prevent hidden cluster outbreaks. As asymptomatic patients are not given much opportunity to undergo antibody testing, ALLEX will support those who wish to be tested for antibodies to prevent the spread of infection.
The full announcement can be found at:
- https://www.nsx.com.au/ftp/news/021738369.PDF and
This news was also highlighted in a Japanese media site, as follows: